UBS Group
CGEM icon

UBS Group’s Cullinan Oncology CGEM Stock Holding History

UBS Group’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.88M Sell
202,385
-69,351
-26% -$891K ﹤0.01% 4625
2025
Q4 		$2.81M Buy
271,736
+83,551
+44% +$754K ﹤0.01% 4637
2025
Q3 		$1.12M Sell
188,185
-123,124
-40% -$902K ﹤0.01% 5478
2025
Q2 		$2.34M Buy
311,309
+32,490
+12% +$261K ﹤0.01% 4649
2025
Q1 		$2.11M Buy
278,819
+43,106
+18% +$414K ﹤0.01% 4658
2024
Q4 		$2.87M Buy
235,713
+50,160
+27% +$721K ﹤0.01% 4374
2024
Q3 		$3.11M Buy
185,553
+25,573
+16% +$454K ﹤0.01% 3547
2024
Q2 		$2.79M Sell
159,980
-6,760
-4% -$144K ﹤0.01% 3420
2024
Q1 		$2.84M Buy
166,740
+25,961
+18% +$401K ﹤0.01% 3590
2023
Q4 		$1.43M Buy
140,779
+37,316
+36% +$331K ﹤0.01% 4162
2023
Q3 		$936K Buy
103,463
+12,396
+14% +$129K ﹤0.01% 4129
2023
Q2 		$980K Sell
91,067
-9,985
-10% -$106K ﹤0.01% 4267
2023
Q1 		$1.03M Buy
101,052
+2,899
+3% +$32K ﹤0.01% 4069
2022
Q4 		$1.04M Buy
98,153
+7,086
+8% +$86.1K ﹤0.01% 4040
2022
Q3 		$1.17M Sell
91,067
-709
-0.8% -$9.55K ﹤0.01% 3625
2022
Q2 		$1.18M Sell
91,776
-33,133
-27% -$376K ﹤0.01% 3604
2022
Q1 		$1.31M Buy
124,909
+103,167
+475% +$1.39M ﹤0.01% 3841
2021
Q4 		$336K Buy
21,742
+17,749
+445% +$354K ﹤0.01% 5288
2021
Q3 		$90K Buy
3,993
+2,027
+103% +$54.2K ﹤0.01% 5900
2021
Q2 		$50K Sell
1,966
-1,127
-36% -$34.7K ﹤0.01% 6427
2021
Q1 		$129K Buy
+3,093
New +$126K ﹤0.01% 5759

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $369M AUM 78.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return